FLT3 and acute myeloid leukemia: Moreover, alternative splicing-derived AML neoantigens represent (e.g., CD44v6) or may represent (e.g., FLT3-Va and NOTCH2-Va) immunotherapeutic targets [131], with CD44v6 CAR T-cells exhibiting anti-cancer killing preclinically [132] and being currently investigated in clinic (NCT04097301).